OMRON Healthcare Co., Ltd. emphasises its commitment to innovation by unveiling new initiatives that advance its global ECG strategy, including increased investment in AI and data-driven approaches.
"Confronting the heart failure 'pandemic' and the shortage of cardiovascular specialists requires new approaches," said Ayumu Okada, president and CEO, OMRON Healthcare Co., Ltd. "By combining innovative technology with strategic partnerships, we aim to take our cardiovascular business to the next stage and help prevent serious cardiac events before they occur."
New ECG strategy
OMRON Healthcare's new ECG strategy integrates AI, clinical diagnostics, and remote monitoring to connect home and hospital. It aims to deliver continuous support across detection, diagnosis, and treatment through clinically validated devices and data-driven solutions. This initiative supports the company's Going for ZERO vision, striving to eliminate adverse cerebro- and cardiovascular events via proactive monitoring and preventive intervention.
"So far, our ECG business has focused primarily on the home, but our aim now is to extend into the diagnostic and treatment settings of medical institutions," added Daisuke Nozaki, general manager, ZERO Event Business Planning Department, OMRON Healthcare Co., Ltd. "By connecting home and hospital, we want to provide continuous support that spans detection, diagnosis and treatment for patients at risk of serious cardiac events."
OMRON Healthcare has increased its strategic investment in Tricog Health India Private Limited, an AI-powered ECG analysis company supporting medical institutions through remote interpretation services. Additionally, it plans to transfer the Heartnote ECG service business from JSR Corporation. Heartnote, a Holter ECG service designed for Japan's aging population, features a thin, lightweight, cordless wearable patch capable of continuous monitoring for up to 7 days.
